RankAlpha logo
Back to Rankings

DRTS

Alpha Tau MedicalC
Nasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-18
View Chart
Current thesis
The bull case is that Japan approval, multiple U.S. trials running in parallel, and several 2026 recruitment/readout checkpoints begin to convert Alpha DaRT from a concept stock into a platform with repeatable clinical and regulatory validation; cash of $76.9 million and management's stated at-least-two-year runway reduce immediate financing pressure [#PR-2026-03-09] [#20F-2026-03-09].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.7.
What can break
Japan approval still requires post-market surveillance and reimbursement work before commercial contribution is visible.
Momentum
96
Value
37
Sentiment
28
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $10.50 · Bear $5.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $14.20
Why
Momentum96 · Δ7d +1.7
Value37 · Δ7d +0.1
Sentiment28 · Δ7d -5.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
96
26% active weight
Current posture
7d trendImproving
Δ7d
+1.7
Δ21d
+7.8
Value
37
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
28
34% active weight
Current posture
7d trendSoftening
Δ7d
-5.0
Δ21d
-15.0
Why this grade

Composite grade C. Momentum 96.3 / Value 36.5 / Sentiment 28.4

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.19B
Beta
1.04
Shares Out
88.01M
P/E (TTM) · Derived
-25.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-32.55
Rev YoY
-
EPS YoY
+107.2%
Gross Margin
-
Op Margin
-
Net Debt
-$63.18M
Current Ratio
7.79
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology